Skip to main content
. 2022 Jan 13;7(1):100378. doi: 10.1016/j.esmoop.2021.100378

Figure 2.

Figure 2

Biliary tract cancers (BTCs): Diagnosis and management algorithm.

BRAF, B-Raf proto-oncogene serine/threonine kinase; CCA, cholangiocarcinoma; dMMR, deficient DNA mismatch repair; eCCA, extrahepatic cholangiocarcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; FGFR, fibroblast growth factor receptor; GBC, gallbladder cancer; HER-2, human epidermal growth factor-2; iCCA, intrahepatic cholangiocarcinoma; IDH-1, isocitrate dehydrogenase-1; MEK, mitogen-activated extracellular signal-regulated kinase; MSI, microsatellite instability; nal-IRI, nanoliposomal irinotecan; NTRK, neurotrophic tyrosine receptor kinase; TMB, tumour mutational burden; TRK, tyrosine receptor kinase. Adapted from2.